Products 

& pipeline

EVG-001 is a kit for the preparation of Gallium-68 DOTATOC for use with PET-CT, currently under review by the FDA. If approved, EVG-001 can be used in conjunction with a PET scan to stage and localize neuroendocrine tumors in adults and children.

‍

Our EVG321 RLTs are highly specific peptide vectors, which bind to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker. For small cell lung carcinoma, CCK2R is expressed with a frequency of 20%-50%. 68Ga-EVG321 has shown encouraging early clinical results (Hörmann et al., 2024). If successful, EVG321 could offer new hope to patients with small cell lung cancer.

EVG311 molecularly targeted tracer binds to a glial cell surface molecule for the treatment of glioblastoma (GBM) and other glial tumors. Effective treatment of GBM is one of the biggest unmet needs in oncology. The 5-year survival rate for GBM is 5.5% in the US, and annually about 13,000 patients in the US receive a GBM diagnosis.

Our EVG332 radiotracer targets a cell surface molecule for the treatment of pancreatic ductal adenocarcinoma (PDAC). The 5-year survival rate for PDAC patients is 11.5%, and significantly lower for patients presenting with distant metastatic disease (3.1%). More than 50% of patients have distant disease at the time of diagnosis. Annually about 33,000 patients in the US receive a distant PDAC diagnosis.

EVG341 molecularly targeted tracer binds to a cancer-specific hormone receptor for the treatment of invasive lobular breast cancer (ILC). ILC represents approximately 10% of all advanced breast cancers, and due to its diffuse and multi-focal nature is difficult to detect. This characteristic also makes breast-conserving surgery more challenging, and its 5-year survival rate drops to 22%. Up to 65% of patients with lobular breast cancer require a second surgery.